Omzo vs TMates: Compounded Semaglutide, Price and Access Compared

Looking for a telehealth GLP-1 option? Omzo vs TMates differ most on pricing model, medication options, clinician access, state coverage, and regulatory status. Quick verdict: Omzo emphasizes clinician-guided plans with compounded semaglutide starting at $179 and tirzepatide at $279, while TMates uses a flat $199/month model with 24/7 U.S. doctor access and free shipping.

Explore Omzo clinician-guided plans

Key differences at a glance

Pricing model and what you pay

Omzo lists semaglutide starting at $179 and tirzepatide starting at $279 as its starting prices for clinician-guided plans. TMates uses a flat $199/month price that remains the same at every dose, with published billing options for multiple month packages. The comparison is direct: Omzo advertises lower starting prices for certain compounds, while TMates emphasizes predictable monthly billing.

See TMates flat $199/month program

Medication selection and how they are provided

Both providers offer compounded semaglutide. Omzo specifically highlights both compounded semaglutide and tirzepatide as part of its compounded medication program, and notes that compounded drugs are not FDA-approved. Omzo also states providers may write prescriptions for branded medications, but Omzo does not sell or ship branded products. TMates focuses on clinically dosed compounded semaglutide formulated in U.S. facilities and provides limited public detail on tirzepatide availability.

Compare Omzo medication options

Clinician access and program oversight

Omzo frames its care as clinician-guided plans reviewed by licensed U.S. providers through third party clinical networks; providers make final prescribing decisions and determine eligibility. TMates highlights 24/7 access to U.S.-based doctors and scheduled virtual check-ins, positioning continuous physician availability as a distinguishing feature.

State coverage, shipping, and logistics

TMates emphasizes licensed coverage in all 50 states and free shipping, with availability based on medical eligibility. Omzo notes fast, discreet delivery but warns that eligibility, state coverage, pharmacy capacity, and renewal terms may change. Both remind users that availability depends on medical eligibility and provider assessment.

Regulatory and safety notes

Both providers explicitly state that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. Omzo adds that its compounded medications are produced in FDA-registered facilities but remain unapproved by FDA. Omzo also cautions that individual results are not guaranteed and that the platform does not create a doctor patient relationship by the initial assessment alone. TMates notes compounded semaglutide uses the same active ingredient as branded options while remaining compounded.

Check TMates availability and doctor access

Final thoughts on Omzo vs TMates

Use Omzo if you prioritize clinician-guided plans that list compounded semaglutide starting at $179 and tirzepatide starting at $279, and if you want providers who may prescribe branded medications but where Omzo does not dispense them. Choose TMates if you prefer a predictable flat $199/month price with 24/7 U.S. doctor access, free shipping, and licensed coverage framed as available across all 50 states. Both note that compounded medications are not FDA-approved and that availability depends on clinician review and eligibility.

Start Omzo enrollment